Loading...
OTCM
IMMB
Market cap57kUSD
Jul 16, Last price  
0.00USD
1D
0.00%
1Q
0.00%
IPO
-100.00%
Name

Immunotech Laboratories Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
Net income
CFO

Profile

Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as a subsidiary of Eco-Petroleum Solutions, Inc.
URL
IPO date
Jan 07, 2002
Employees
Domiciled in
US
Incorporated in
US

Valuation

No data to show